Department of Radiation Hazard Evaluation, Institute of Radiation Medicine of Chinese Academy of Medical Science and Peking Union Medical College, Tianjin 300192, P.R. China.
Int J Oncol. 2013 Mar;42(3):985-92. doi: 10.3892/ijo.2013.1785. Epub 2013 Jan 22.
A major concern in cancer therapy is resistance of tumors such as human non-small cell lung cancer and esophageal cancer to radiotherapy. Intrinsic radioresistance of these cancer cells limits therapeutic efficiency. Here, we determined in two cancer cell lines the potential radiosensitizing activity of Tat-SmacN7, a small molecule compound, which mimics the activity of Smac, a mitochondrial protein released during apoptosis. We found that Tat-SmacN7 can enter the cells and promote RNA expression and the activity of caspase-3, -8 and -9 and sensitized the cancer cells to radiation with a sensitization enhancement ratio (SER) of 1.5-1.6. Tat-SmacN7 radiosensitization was mediated by both extrinsic and intrinsic apoptosis pathways through activation of caspases. Consistently, blockage of caspase activation, through treatment with a caspase inhibitor, z-VAD-fmk, inhibited apoptosis and abrogated Tat-SmacN7 radiosensitization. Our study demonstrates that Tat-SmacN7 also has radiosensitization effects in vivo, so it could be further developed as a novel class of radiosensitizers for the treatment of radioresistant human non-small cell lung cancer and esophageal cancer.
癌症治疗中的一个主要问题是肿瘤对放疗的耐药性,如人非小细胞肺癌和食管癌。这些癌细胞的内在放射抵抗性限制了治疗效果。在这里,我们在两种癌细胞系中确定了 Tat-SmacN7 的潜在放射增敏活性,Tat-SmacN7 是一种小分子化合物,模拟了线粒体蛋白 Smac 在细胞凋亡过程中释放的活性。我们发现 Tat-SmacN7 可以进入细胞,并促进 RNA 表达和 caspase-3、-8 和 -9 的活性,将癌细胞对辐射的敏感性提高了 1.5-1.6 倍。Tat-SmacN7 通过激活半胱天冬酶来介导细胞外和细胞内凋亡途径的放射增敏作用。一致地,通过用半胱天冬酶抑制剂 z-VAD-fmk 处理来阻断半胱天冬酶的激活,抑制了细胞凋亡并消除了 Tat-SmacN7 的放射增敏作用。我们的研究表明,Tat-SmacN7 在体内也具有放射增敏作用,因此它可以进一步开发为一种新型的放射增敏剂,用于治疗对放疗有抗性的人非小细胞肺癌和食管癌。